Endiya Partners, in its latest report titled ‘India’s Biopharma Moment: Perspectives from DEMO Biotech,’ has highlighted a significant shift underway in India’s pharmaceutical landscape, with the country evolving from a global leader in generics to a fast-growing, cost-effective hub for biopharma innovation.

The report notes that India is currently at an inflection point, supported by favourable policy measures, regulatory reforms and the emergence of high-quality clinical-stage assets gaining global recognition. It identifies India’s advantages in rapid patient recruitment and efficient clinical development—referred to as ‘Recruitment Alpha’ and ‘More Shots on Goal’—as key differentiators in the global R&D ecosystem.

Globally, the biopharma industry is undergoing a structural reset, with research and development costs rising to approximately USD 2.2 billion per asset and development timelines stretching to nearly 100 months. This, coupled with a growing focus on complex therapies such as gene therapies and mRNA, a looming USD 300 billion patent cliff and geopolitical uncertainties, is driving demand for more agile and cost-efficient innovation ecosystems.

India continues to play a critical role globally, supplying around 20 percent of generic medicines and over 60 percent of vaccines. The report highlights that the country is now transitioning toward innovation-led capabilities in advanced biotherapeutics and deep-tech platforms.

India’s bioeconomy has witnessed rapid growth, expanding from USD 10 billion in 2014 to over USD 195 billion in 2026, and is projected to reach nearly USD 300 billion by 2033. The ecosystem has also scaled significantly, with more than 2,500 startups, around 100 incubators and over 600 research institutes.

Government initiatives such as the INR 10,000 crore Biopharma Shakti scheme and the INR 1,00,000 crore Research, Development and Innovation (RDI) Fund are seen as key enablers of this transformation. Additionally, recent regulatory reforms, including a 45-day approval timeline and prior intimation pathways, are expected to reduce administrative delays and shorten development cycles by 90 to 120 days.

The report also points to growing global validation of Indian innovation, citing milestones such as the USD 1.9 billion AbbVie–IGI deal, the US FDA’s acceptance of Wockhardt’s Zaynich NDA and the advancement of Eyestem’s cell therapy into Phase II trials. These developments indicate that Indian biotech intellectual property is gaining parity with global innovation hubs.

Despite these advancements, challenges remain, including gaps in pilot-scale GMP infrastructure, late-stage funding, talent availability and translational research capabilities.

Looking ahead, the report outlines four key pillars to sustain growth: blended finance to de-risk innovation, development of industrial intelligence, strengthening translational infrastructure and building a dynamic regulatory framework.

Industry stakeholders emphasised the need for continued ecosystem collaboration. 

Dr Ramesh Byrapaneni of Endiya Partners, said, “The government has done a good job so far and while policy support will continue to play a role, it is up to investors, incubators, startups and corporates to take the ecosystem forward.”

Dr Vedha Sampathkumar added that India offers a compelling combination of clinical depth, technical talent and cost efficiency, positioning it to address complex global healthcare challenges at significantly lower costs.

With sustained policy backing and industry participation, the report concludes that India is well-positioned to emerge as a global hub for high-quality, cost-efficient biopharma innovation.